Marlies van Dijk
Overview
Explore the profile of Marlies van Dijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roodenburg S, van Dijk M, Augustijn S, Klooster K, Slebos D, Hartman J
ERJ Open Res
. 2024 Oct;
10(3).
PMID: 39371297
Background: Assessment of static hyperinflation severity is crucial to identify COPD patients eligible for lung volume reduction. The current recommendation of residual volume ≥175% predicted may need to be reconsidered...
2.
Roodenburg S, Klooster K, Hartman J, Kontogianni K, Brock J, Dittrich A, et al.
Respiration
. 2024 Sep;
104(1):58-68.
PMID: 39284292
Introduction: Currently, there is a lack of bronchoscopic lung volume reduction options that do not depend on fissure integrity. Endobronchial coils have been extensively studied to address this need but...
3.
van Dijk M, Van De Wauwer C, Koster T, Klooster K, Slebos D
Interdiscip Cardiovasc Thorac Surg
. 2024 May;
38(5).
PMID: 38724230
Objectives: Bronchoscopic lung volume reduction with endobronchial valves is a guideline treatment leading to improved pulmonary function, exercise tolerance and quality of life, in patients with advanced emphysema, severe hyperinflation...
4.
Hartman J, Klooster K, Koster T, Carpaij O, van Dijk M, Slebos D
Respiration
. 2023 Nov;
102(12):1003-1006.
PMID: 37939683
Introduction: Endobronchial valve (EBV) treatment has been shown to be beneficial for patients with severe emphysema. The forced expiratory volume in 1 s (FEV1) was found to be significantly higher...
5.
van Dijk M, Sachs A, Kerstjens H
Ned Tijdschr Geneeskd
. 2023 Aug;
167.
PMID: 37609922
COPD is the third most common chronic disease in the Netherlands and the number of patients is still rising. This article reviews causes of COPD, assesses the role of spirometry...
6.
Hartman J, Roodenburg S, van Dijk M, Koster T, Klooster K, Slebos D
ERJ Open Res
. 2023 Jul;
9(4).
PMID: 37465561
Background: Bronchoscopic lung volume reduction using endobronchial valves (EBV) has been shown to be beneficial for severe emphysema patients. The most important predictor of treatment response is absence of collateral...
7.
Koster T, Charbonnier J, Pruim J, Gietema H, Posthuma R, Vanfleteren L, et al.
Am J Respir Crit Care Med
. 2023 May;
208(4):495-498.
PMID: 37192444
No abstract available.
8.
Buiter-van der Meer A, Mooren K, Slebos D, van Dijk M
Ned Tijdschr Geneeskd
. 2023 Apr;
167.
PMID: 37052405
COPD (Chronic Obstructive Pulmonary Disease) affects an estimated 600,000 Dutch citizens. This chronic disease often has an unpredictable and sometimes a very invalidating course, despite various treatment options. It is...
9.
Roodenburg S, Slebos D, van Dijk M, Koster T, Klooster K, Hartman J
Respir Med
. 2023 Mar;
210:107175.
PMID: 36858325
Background: Bronchoscopic lung volume reduction using endobronchial valves (EBV) is a treatment option for selected patients with advanced emphysema. The treatment significantly improves pulmonary function, exercise capacity, quality of life,...
10.
Bronchoscopic Lung Volume Reduction in Patients with Emphysema due to Alpha-1 Antitrypsin Deficiency
Everaerts S, Hartman J, van Dijk M, Koster T, Slebos D, Klooster K
Respiration
. 2022 Dec;
102(2):134-142.
PMID: 36549279
Background: Bronchoscopic lung volume reduction using one-way endobronchial valves (EBVs) is a valid therapy for severe emphysema patients. However, alpha-1 antitrypsin (AAT)-deficient patients were excluded from the majority of clinical...